Berenberg Bank set a €145.00 ($168.60) price objective on MorphoSys (ETR:MOR) in a report released on Monday morning, Borsen Zeitung reports. The firm currently has a buy rating on the stock.
Several other research analysts have also recently issued reports on the stock. Royal Bank of Canada set a €130.00 ($151.16) price objective on shares of MorphoSys and gave the company a buy rating in a report on Tuesday, December 10th. Goldman Sachs Group set a €114.00 ($132.56) price objective on shares of MorphoSys and gave the company a neutral rating in a report on Monday. JPMorgan Chase & Co. set a €150.00 ($174.42) price objective on shares of MorphoSys and gave the company a buy rating in a report on Monday. Independent Research set a €110.00 ($127.91) price objective on shares of MorphoSys and gave the company a neutral rating in a report on Friday, November 1st. Finally, Deutsche Bank set a €129.00 ($150.00) target price on shares of MorphoSys and gave the stock a buy rating in a report on Friday, December 6th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. MorphoSys presently has an average rating of Hold and an average target price of €122.71 ($142.69).
MorphoSys stock opened at €121.30 ($141.05) on Monday. The firm has a 50 day simple moving average of €123.78 and a 200-day simple moving average of €106.46. The company has a debt-to-equity ratio of 9.78, a current ratio of 7.80 and a quick ratio of 7.63. The stock has a market capitalization of $3.82 billion and a PE ratio of -39.88. MorphoSys has a 12-month low of €79.70 ($92.67) and a 12-month high of €131.00 ($152.33).
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Recommended Story: Price to Earnings Ratio (PE) Basics
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.